44% of Canadians Will Get Cancer: This 1 Stock Will Skyrocket!

IMV Inc. (TSX:IMV)(NASDAQ:IMV) specializes in making immunotherapies more effective, add the stock to your TFSA or RRSP today!

| More on:
Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

It’s a sad reality that 44% of Canadians will get cancer and 25% of Canadians are expected to die from it.

One of the main components of cancer treatment is immunotherapy. There are two types of immunotherapy: activation immunotherapy and suppression immunotherapy.

As the name suggests, activation immunotherapy triggers an immune response, whereas suppression immunotherapies reduce a response.

For cancer specifically, there are two ways to alter the immune system to fight back. This includes the stimulating the immune system to attack cancer cells and to give man-made immune system proteins to strengthen it.

This is where IMV (TSX:IMV)(NASDAQ:IMV) comes in. IMV is a clinical-stage bio-pharmaceutical company with a product that enables the controlled and prolonged exposure of antigens to boost the immune system. In layman’s terms, it’s a form of activation immunotherapy.

It’s a good investment due to its product’s ability to condition the immune system and its increasing revenues.

Conditioning the immune system

Before we dive into the importance of the immune system when it comes to cancer treatment, let’s focus on defining what an antigen is.

For the less biology inclined (my prior self included), antigens are substances that stimulate an immune response. Antigens are responsible for activating lymphocytes which are white-blood cells that fight infections.

The two types of antigens are foreign antigens and auto antigens. As the name suggests, foreign antigens originate from outside of the body such as those produced by viruses and from snake venom. Auto-antigens originate from within the body.

Antigens trigger the production of antibodies that are used to protect the immune system. Thus, through the exposure of antigens, patients are conditioned to produce more antibodies that attack harmful cancer cells. By conditioning the immune system, it can fight cancer cells more readily.

From an investors point of view, this is a very good reason to invest in the company as the methods and technology being used by IMV are very advanced. In the pharmaceutical industry, innovation is key, which means that a company like IMV is poised to deliver stellar returns for investors. The company’s flagship product is called DPX-Survivac and it’s getting a lot of publicity.

Increasing revenues

Due to the high costs of research and development, the success of a pharmaceutical company can’t be measured based on net income alone.

In fiscal 2018, IMV spent $13 million on research and development compared to $0.48 million in revenue. Despite this significant gap, I believe IMV is doing well as its revenues have increased from $0.13 million in fiscal 2015 to $0.48 million in fiscal 2018.

Growing revenues indicate that clients are interested in the products that IMV has to offer.

Bottom line

By focusing on the controlled exposure of antigens to the immune system, IMV plans to bring a product to the market that will revolutionize cancer treatments. Its product will help to condition a cancer patient’s immune system, ultimately rendering it more effective in fighting cancer cells.

Further, IMV’s revenue has increased from $0.13 million in fiscal 2015 to $0.48 million in fiscal 2018, which is testament to the interest around the company’s products.

Ultimately, investors looking to diversify with a pharmaceutical stock should look into buying IMV.

If you liked this article, click the link below for exclusive insight.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chen Liu has no position in any of the stocks mentioned.

More on Investing


3 Growth Stocks That Could Double Your Investments in the Next 3 Years

Given their growth prospects, I am bullish on the following three growth stocks.

Read more »

Canadian Dollars
Dividend Stocks

Passive-Income Investing: How You Can Churn Out $445/Month for the Rest of 2022

Canadians crushed by inflation should look to make big passive income in 2022 with stocks like Freehold Royalties Ltd. (TSX:FRU)…

Read more »

calculate and analyze stock
Dividend Stocks

2 TSX Stocks to Buy With Dividends Yielding More Than 3%

Are you looking for some great income stocks that can provide growth, too? Here are two stellar TSX stocks to…

Read more »

edit Balloon shaped as a heart
Dividend Stocks

Dividend Lovers: 3 U.S. Stocks You Haven’t Heard About

Don't just stick to Canadian companies for a great dividend, consider these U.S. stocks you probably haven't even heard of.

Read more »

Happy diverse people together in the park

Canadians: 3 Top Growth Stocks That Could Make You Rich This Decade

Canadian investors should be eager to snatch up promising growth stocks like goeasy Ltd. (TSX:GSY) in the final weeks of…

Read more »

money cash dividends
Dividend Stocks

How to Invest $10,000 Over the Next 5 Years

Those looking to put $10,000 to work in this rather uncertain and volatile market may want to consider these three…

Read more »

Growing plant shoots on coins

3 High-Growth TSX Stocks That Could Soar

These three TSX growth stocks are trading ultra-cheap, giving them the potential to soar significantly when the market rebounds.

Read more »

TFSA and coins
Dividend Stocks

TFSA Investors: 2 Incredible Deals to Buy in August

Here are two TSX stocks investors can consider for their TFSA contribution this year.

Read more »